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ABSTRACT 
Androgen receptor (AR) is necessary for normal male phenotype development and 
essential for spermatogenesis. AR is a classical steroid receptor mediating actions of male sex 
steroids – testosterone and 5α-dihydrotestosterone. Numerous coregulators interact with the 
receptor and regulate AR activity on target genes. 
This study deals with the characterization of androgen receptor-interacting protein 4 
(ARIP4). ARIP4 binds DNA, interacts with AR in vitro and in cultured yeast and mammalian 
cells, and modulates AR-dependent transactivation. ARIP4 is an active DNA-dependent 
ATPase, and this enzymatic activity is essential for the ability of ARIP4 to modulate AR 
function. On the basis of sequence homology in its ATPase domain, ARIP4 belongs to the 
SNF2 family of proteins involved in chromatin remodeling, DNA repair, and homologous 
recombination. Similar to its closest homologs ATRX and Rad54, ARIP4 does not seem to be 
a classical chromatin remodeling protein in that it does not appear to form large protein 
complexes in vivo or remodel mononucleosomes in vitro. However, ARIP4 is able to generate 
superhelical torsion on linear DNA fragments. ARIP4 is covalently modified by SUMO-1, 
and mutation of six potential SUMO attachment sites abolishes the ability of ARIP4 to bind 
DNA, hydrolyze ATP, and activate AR function. ARIP4 expression starts in early embryonic 
development. In mouse embryo ARIP4 is present mainly in the neural tube and limb buds. In 
adult mouse tissues ARIP4 expression is virtually ubiquitous. In mouse testis ARIP4 is 
expressed in the nuclei of Sertoli cells in a stage-dependent manner. ARIP4 is also present in 
the nuclei of Leydig cells, spermatogonia, pachytene and diplotene spermatocytes. Testicular 
expression pattern of ARIP4 does not differ significantly in wild-type, FSHRKO, and LuRKO 
mice. In the testis of hpg mice, ARIP4 is found mainly in interstitial cells and has very low, if 
any, expression in Sertoli and germ cells. Heterozygous Arip4+/– mice are fertile and appear 
normal; however, they are haploinsufficient with regard to androgen action in Sertoli cells. In 
contrast, Arip4–/– embryos are not viable. They have significantly reduced body size at E9.5 
and die by E11.5. Compared to wild-type littermates, Arip4–/– embryos possess a higher 
percentage of apoptotic cells at E9.5 and E10.5. Fibroblasts derived from Arip4–/– embryos 
cease growing after 2-3 passages and exhibit a significantly increased apoptosis and decreased 
proliferation rate than cells from wild-type embryos. Our findings demonstrate that ARIP4 
plays an essential role in mouse embryonic development. In addition, testicular expression 
and AR coregulatory activity of ARIP4 suggest a role of ARIP4-AR interaction in the somatic 
cells of the testis. 
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ABBREVIATIONS 
AF  activation function 
AMH  anti-Müllerian hormone 
ANPK  androgen receptor-interacting nuclear kinase 
AR  androgen receptor 
ARE  androgen response element 
ARIP4  androgen receptor-interacting protein 4 
ARKO  androgen receptor knockout 
ATP  adenosine triphosphate 
ATRX  α-thalassemia, mental retardation, X-linked 
bp  base pair 
cAMP  cyclic adenosine-3’-5’-monophosphate 
CBP  cAMP responsive element binding (CREB)-binding protein 
DBD  DNA-binding domain 
Dhh  Desert hedgehog 
DHT  5α-dihydrotestosterone 
ds  double-stranded 
E  embryonic day (day post conception) 
EGFP  enhanced green fluorescent protein 
Fgf9  fibroblast growth factor 9 
FSH  follicle stimulating hormone 
FSHR  follicle stimulating hormone receptor 
FSHRKO follicle-stimulating hormone receptor knockout 
FXRβ  farnesoid receptor β  
GnRH  gonadotropin releasing hormone 
GR  glucocorticoid receptor 
GST  glutathione S-transferase 
H  hinge 
HAT  histone acetylase 
HDAC  histone deacetylase 
hpg  hypogonadal 
HSP  heat shock protein 
kDa  kilodalton 
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LBD  ligand-binding domain 
LH  luteinizing hormone 
LuRKO luteinizing hormone receptor knockout 
MAPK  mitogen-activated protein kinase 
MEF  mouse embryonic fibroblast 
MMTV mouse mammary tumor virus 
NCoR  nuclear receptor corepressor 
NLS  nuclear localization signal 
NTD  amino-terminal domain 
PCAF  p300/CBP-associated factor 
PCR  polymerase chain reaction 
Pdgf-A platelet-derived growth factor A 
PGC  primordial germ cell 
PIAS  protein inhibitor of activated STAT 
PR  progesterone receptor 
RT-PCR reverse transcriptase – polymerase chain reaction 
SCARKO Sertoli cell-selective androgen receptor knockout 
Sf1  steroidogenic factor 1 
SMRT  silencing mediator for retinoic acid and thyroid hormone receptors 
SNURF small nuclear really interesting new gene (RING) finger 
Sox9  Sry-like high mobility group (HMG)-box 9 
SRC  steroid receptor coactivator 
Sry  sex-determining on Y chromosome 
SUMO  small ubiquitin-related modifier 
SWI/SNF switch/sucrose non-fermenting 
T  testosterone 
TBP  TATA-binding protein 
Tfm  testicular feminization 
TRAP  thyroid hormone receptor-associated protein  
Wnt4  wingless-related MMTV integration site 4 
Wt1  Wilm’s tumor 1 
ZFR  zinc finger region 
 
REVIEW OF THE LITERATURE  
 10 
INTRODUCTION 
The coregulatory proteins interact with AR and modulate its transcriptional activity on 
target genes. These coregulators regulate AR activity by multiple mechanisms, such as 
promoting chromatin remodeling, DNA binding, recruitment of general transcription factors 
associated with RNA polymerase II complex to androgen-responsive promoters (Heinlein and 
Chang 2002, Jänne et al. 2000, Kang et al. 2004). Targeting such coregulators to indirectly 
inactivate AR signaling in prostate tumors is a promising approach to control prostate cancer 
progression and enhance the response to androgen ablation therapy (Heinlein and Chang 
2004, Scher and Sawyers 2005). 
In a search for novel proteins interacting with AR the androgen receptor-interacting 
protein 4 (ARIP4) was identified. ARIP4 is an active DNA-dependent ATPase modulating 
AR-dependent transcription both in vivo and in vitro. ARIP4 expression in male germ cells 
implies that the protein has also AR-independent functions in spermatogenesis. Moreover, the 
study of Arip4 knockout mouse model demonstrated the essential role of ARIP4 in mouse 
embryonic development. 
 
REVIEW OF THE LITERATURE 
1. Early development of mouse embryo 
Mouse embryonic development is a relatively well-studied process (Hogan et al. 1994, 
Kaufman 1992) (Edinburgh Mouse Atlas Project, genex.hgu.mrc.ac.uk). During the early 
embryonic days, the fertilized egg undergoes significant changes as outlined in Table 1. 
After about 4.5 days post-conception (embryonic day (E) 4.5) embryo implantation 
occurs. At this time the embryo contains three distinct tissue lineages – trophectoderm, 
primitive endoderm, and primitive ectoderm (epiblast). Primitive ectoderm and extra-
embryonic ectoderm form the core of the egg cylinder that is covered by visceral endoderm, 
whereas parietal endoderm covers the inner surface of the mural trophectoderm. Secretions of 
parietal endoderm cells at about E5.0 form a thick basement membrane that serves as a major 
barrier between the maternal and fetal environments during the early embryonic stages. 
Parietal endoderm, trophoblast cells, and a basement membrane between them constitute the 
parietal yolk sac. Simultaneously, placenta development starts from the formation of the 
ectoplacental cone that becomes filled with maternal blood (Hogan et al. 1994). 
REVIEW OF THE LITERATURE  
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During E5.5–E7.5, the egg cylinder differentiates into embryonic and extra-embryonic 
regions, and a proamniotic cavity forms. Later, amnion and chorion divide the proamniotic 
cavity into amniotic, exocoelomic, and ectoplacental cavities. At E6.5, when the embryonic 
axis is already determined, the primitive ectoderm develops into embryonic endoderm, 
mesoderm, and ectoderm (Hogan et al. 1994, Kaufman and Bard 1999).  
About one day later (E7.5), the neural system starts to develop. The neural plate forms 
in the rostral part of the embryonic axis, and early head folds elevate. Half a day later, the 
neural folds begin to fuse and three primary brain vesicles – forebrain, midbrain, and 
hindbrain – appear at E8.5–E9.0 (Kaufman and Bard 1999).  
The heart and vascular system start to develop in parallel with the neural system at 
E7.5–E8.0. Primitive blood vessels appear at E8.0 simultaneously with the primitive heart 
tube that starts contracting around E8.5 (Conway et al. 2003). At this time embryonic and 
Table 1. Features of the mouse embryo at early stages of development. Adapted from (Kaufman 1992, 
Kaufman and Bard 1999) 
Principal features 
Embryonic 
day 
2-cell embryo 1.5 
8-cell embryo (morula) 2.5 
16-cell embryo 3.0 
Blastocyst 4.0 
Attaching blastocyst 4.5 
Implantation. Early egg cylinder. Ectoplacental cone. Reichert’s membrane 5.0 
Egg cylinder differentiation. Proamniotic cavity 6.0 
Amnion. First evidence of the allantois. Precursors of primordial germ cells (PGCs) 
in the extra-embryonic mesoderm 
7.0 
Neural plate development and neural folds formation 7.5 
First somites. Neural folds begin to close. PGCs at the base of allantois 8.0–8.5 
Axial rotation (“turning”). PGCs in the hindgut endoderm 8.5–9.0 
Cephalic neural folds elevate and fuse. Rostral neuropore closes. Three primitive 
brain vesicles form. Urogenital ridges clearly seen 
9.0–9.5 
Caudal neuropore forms. Forelimb buds appear. PGCs in the gonadal components of 
the urogenital ridges 
9.5–10.25 
Caudal neuropore closes. Hindlimb and tail buds appear 10.25–10.75 
Distinct genital ridges with PGCs 11.0 
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extra-embryonic blood circulations fuse, and primitive nucleated red blood cells originating 
from the blood islands in visceral yolk sac appear in the embryonic vasculature. 
Around day E8.0–E8.5, the mouse embryo undergoes axial rotation. During this 
process the embryo reverses the initial location of its germ layers and becomes completely 
surrounded by extra-embryonic membranes – amnion and visceral yolk sac (Hogan et al. 
1994, Kaufman and Bard 1999). 
By E9.0 the heart has relatively well-defined regions that later increase in volume, 
differentiate, and develop into components of the four heart chambers. At this time, the heart 
beats regularly and powerfully and the primitive circulation is established (Conway et al. 
2003). Vascular system differentiates, and first evidences of asymmetry appear. The primitive 
liver forms at E10.5, rapidly enlarges and becomes the principal source of hemopoiesis at 
E11.0–E11.5 (Kaufman and Bard 1999). 
Thus, at E11.5 the mouse embryo has quite advanced and actively developing nervous 
and vascular systems, starting the development of other organs.  
 
2. Male sex determination 
2.1 Gonadal morphology 
Alkaline phosphatase-positive primordial germ cells (PGCs) can be detected in the 
extra-embryonic mesoderm of the posterior amniotic fold already at E7.0–E7.5 (Table 1) 
(Ginsburg et al. 1990, Hogan et al. 1994, Kaufman and Bard 1999). At E8.0, these cells 
migrate towards the base of allantois and then to the hindgut endoderm. Most germ cells get 
to the base of allantois by E8.5–E9.0 and continue to migrate towards the urogenital ridges 
(McLaren 2003). During migration germ cells undergo active mitosis. At E9.5, the urogenital 
ridges can be clearly seen extending from the mid-trunk to the mid-tail region (Hogan et al. 
1994). At E10.0–E10.25, the lateral part of each urogenital ridge forms the mesonephros, and 
the medial part forms the gonads. About this time Wolffian (or mesonephric) ducts start to 
develop, whereas Müllerian (or paramesonephric) ducts form one day later, but regress in the 
males soon afterwards. At E11.5, the gonads contain large numbers of germ cells. At this time 
the gonads are indifferent, that is, their morphology does not reflect the sex of the embryo 
(Fig. 1) (Brennan and Capel 2004). Sertoli cell precursors start to differentiate in male gonads 
at E11.5. Increased proliferation of interstitial cells, migration of mesonephric cells, 
vascularization, and development of Leydig cells follow Sertoli cell differentiation (Brennan 
and Capel 2004). 
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At E12.5, the testicular cords extend and incorporate the germ cells and Sertoli cells, 
and fetal Leydig cells are present in the interstitial tissue (Fig. 1) (Brennan and Capel 2004, 
Karl and Capel 1998). Primitive seminiferous tubules form by E13.0, and germ cells continue 
to proliferate within these tubules until mitotic arrest at about E14.0 (Hogan et al. 1994). After 
birth, germ cells move to the periphery of the seminiferous tubules, so that on postnatal days 
3–7 type A spermatogonia appear lying on the basement membrane (Brennan and Capel 2004, 
Hogan et al. 1994). 
 
2.2 Molecular mechanisms of male sex determination 
Three proteins – sex-determining on Y chromosome (Sry), Sry-like high mobility 
group (HMG)-box 9 (Sox9), and fibroblast growth factor 9 (Fgf9) – together with other 
growth factors and pro-testis proteins are actively involved in male sex determination (Fig. 1) 
(Ronfani and Bianchi 2004). 
Around E10.5, Wilm’s tumor 1 protein (Wt1) along with signals from the insulin 
receptor family members (insulin receptor (Insr), insulin receptor-related receptor (Insrr), and 
insulin-like growth factor 1 receptor (Igf1r)) activate Sry expression in the genital ridges 
(Brennan and Capel 2004, Hogan et al. 1994, Park and Jameson 2005). Sry acts either as a 
classical transcription factor or as a chromatin remodeler to initiate Sertoli cell differentiation 
and male development (Brennan and Capel 2004, Ronfani and Bianchi 2004). At E11.5, the 
 
 
 
Fig. 1. Scheme of the male differentiation cascade and gonadal morphology. Gc, germ cell; Sc, Sertoli cell; 
fLc, fetal Leydig cell; PM, peritubular myoid cell; CV, coelomic vessel. Adapted from (Brennan and Capel 
2004, Ronfani and Bianchi 2004). 
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differentiating precursors of Sertoli cells start expressing Sox9. Sox9 cooperates with orphan 
nuclear receptor steroidogenic factor 1 (Sf1) to activate the expression of the anti-Müllerian 
hormone (AMH) that promotes regression of Müllerian ducts (Ronfani and Bianchi 2004). In 
addition, Sox9 upregulates expression of Fgf9 that is essential for proliferation of Sertoli cell 
precursors. A recently proposed model suggests the establishment of a feed-forward loop 
where Fgf9 promotes expansion of Sertoli cell precursors that secrete more Fgf9. This effect 
stabilizes Sox9 expression, and represses the ovary-promoting gene Wnt4 (wingless-related 
MMTV integration site 4) (Kim et al. 2006). Wnt4 is essential for ovarian cell differentiation 
and function, and it may also be involved in early testis development (Jeays-Ward et al. 2004, 
Vainio et al. 1999). In addition to stimulating the proliferation of Sertoli cell precursors, Fgf9 
promotes migration of mesonephric cells. Sprouty2 – a membrane-associated inhibitor of 
tyrosine kinase signaling – is involved in the regulation of migration (Chi et al. 2006). 
Differentiating Sertoli cells also express Desert hedgehog (Dhh) and platelet-derived growth 
factor A (Pdgf-A) that promote Leydig cell differentiation and Sf1 expression (Fig. 1) 
(O'Shaughnessy et al. 2005). In differentiating Leydig cells Sf1 activates expression of 
proteins involved in testosterone biosynthesis (Park and Jameson 2005). Testosterone acts 
through the androgen receptor expressed from E12.5–E13.0 onwards in the mesonephric 
mesenchyme around the differentiating Wolffian ducts (Cooke et al. 1991, Crocoll et al. 
1998), and supports survival and differentiation of Wolffian ducts into the vas deferens, 
seminal vesicles, and epididymis. In females, Wnt4 signaling suppresses testosterone 
biosynthesis (Heikkilä et al. 2005), Wolffian ducts regress due to the absence of testosterone 
signaling, whereas Müllerian ducts persist due to the presence of Wnt4 signaling and the 
absence of AMH (Vainio et al. 1999). 
The male sex determination mechanism was characterized using several knockout 
mouse models (Brennan and Capel 2004). Male mice with Sry deletion develop as fertile 
females (Lovell-Badge and Robertson 1990). Conditional knockout of Sox9 in the developing 
gonads interferes with Sertoli cell differentiation and seminiferous tubule formation 
(Chaboissier et al. 2004). Most gonads in Fgf9 knockout male mice are fully sex-reversed and 
do not express male markers downstream of Sry (Colvin et al. 2001). Sf1 knockout mice lack 
adrenal glands and gonads (Luo et al. 1994, Sadovsky et al. 1995), whereas Dhh knockout 
male mice exhibit differentiation defects of fetal Leydig cells (Yao et al. 2002).  
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3. Cellular organization of adult testis 
Morphologically, the adult testis is organized into seminiferous tubules separated by 
the interstitial space (Russell et al. 1990). Spermatogenesis takes place within the 
seminiferous tubules, where Sertoli cells and germ cells are located. Sertoli cells and germ 
cells are surrounded by peritubular myoid cells. The interstitial space contains blood and 
lymphatic vessels, and Leydig cells (Fig. 2). 
 
3.1 Sertoli cells 
Sertoli cells support spermatogenesis by maintaining the integrity and 
compartmentalization of the seminiferous epithelium, delivering nutrients to the germ cells, 
and regulating the spermatogenic cycle (Russell et al. 1990). In neonatal testis, Sertoli cells 
are immature and able to proliferate. Sertoli cells undergo extensive proliferation, growth, and 
functional maturation during the postnatal period in order to support spermatogenesis after 
puberty. The maturation involves the loss of proliferative ability, formation of tight junctions, 
and changes in gene expression. Testosterone, but not FSH, is required for Sertoli cell 
proliferation in male mice during fetal and early neonatal life (Johnston et al. 2004). 
However, later in life thyroid hormone, androgens, follicle-stimulating hormone (FSH), and 
paracrine factors secreted by germ cells regulate and modulate Sertoli cell maturation (Sharpe 
 
 
 
Fig. 2. Scheme of the cellular organization of the testis. Adapted from (Russell et al. 1990). 
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et al. 2003). FSH and thyroid hormone both induce AR expression and suppress AMH 
expression in maturating Sertoli cells (Arambepola et al. 1998, Holdcraft and Braun 2004, 
Tan et al. 2005b). The increase in concentrations of FSH and testosterone at puberty and 
increased expression of AR enable final maturation of Sertoli cells (Sharpe et al. 2003). 
Recent studies of Sertoli cell-selective Ar knockout (SCARKO) mice have shown that Sertoli 
cells proliferate and express maturation markers even in the absence of AR expression. 
However, SCARKO Sertoli cells are unable to support late meiotic and post-meiotic germ 
cells (Tan et al. 2005b). The presence of immature Sertoli cells in adult testis results in 
spermatogenesis disorders (Sharpe et al. 2003). Mature Sertoli cells express FSH receptor 
(FSHR) and AR, and thus integrate androgen and FSH signaling. FSH receptor is expressed in 
Sertoli cells in a stage-dependent fashion, having the highest levels at stages XIII–II and the 
lowest levels at stages VII–VIII (Heckert and Griswold 1991, Tan et al. 2005b). Similar to 
FSHR, AR is also expressed in a stage-dependent manner in Sertoli cells, with the highest 
expression levels detected at stages VII–VIII (Bremner et al. 1994, Sharpe et al. 2003, Suarez-
Quian et al. 1999, Tan et al. 2005b). The stage-specific patterns of protein expression in 
Sertoli cells most probably result from the combination of hormone actions with signals 
coming from developing germ cells (Griswold 1995, Tan et al. 2005a). 
 
3.2 Leydig cells 
The main function of the Leydig cells is the production of testosterone from 
cholesterol. There are two generations of Leydig cells, arising in mammals in distinct periods 
of life. 
The first generation develops during fetal life and is responsible for male sex 
determination. These cells differentiate from mesenchymal-like stem cells and start producing 
testosterone around E12.5. Neither the initial differentiation nor testosterone production in 
mouse fetal Leydig cells depend on luteinizing hormone (LH) signaling (O'Shaughnessy et al. 
1998, Zhang et al. 2001). However, as noted before, the differentiation of fetal Leydig cells 
appears to depend on the Sertoli cell products Dhh and Pdgf-A (Fig. 1) (O'Shaughnessy et al. 
2005). Fetal Leydig cells have no mitotic activity and gradually regress during late fetal 
period and after birth (Habert et al. 2001).  
The second Leydig cell generation arises during puberty and supports 
spermatogenesis. The adult Leydig cells develop from undifferentiated mesenchymal-like 
cells that proliferate neonatally and differentiate into precursor Leydig cells. During puberty, 
these cells mature, start to express Leydig cell-specific markers, such as LH receptor, and 
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increase testosterone production (Habert et al. 2001). The first adult Leydig cells start to 
appear in the mouse around postnatal day 7, their number reaches adult levels around 
postnatal day 30 (O'Shaughnessy et al. 2002, O'Shaughnessy et al. 2005). Growth and 
maturation of the adult Leydig cell population depend on LH signaling (Ahtiainen et al. 2007, 
Huhtaniemi et al. 2006). In addition, androgens, acting either directly on the Leydig cells or 
through the peritubular myoid cells, are required for normal Leydig cell development 
(O'Shaughnessy et al. 2005, Zhang et al. 2004). 
 
3.3 Peritubular myoid cells 
Peritubular myoid cells originate from mesonephric cells that migrate to the 
developing gonads between E11.5–E13.5. Peritubular myoid cells express actin filaments and 
other cytoskeletal proteins such as myosin, desmin, and α-actinin, and provide structural 
integrity to the seminiferous tubule. Due to the ability to contract, peritubular myoid cells 
mediate the transport of spermatozoa and testicular fluid though seminiferous tubules. In 
addition, these cells take part in the regulation of spermatogenesis by expressing components 
of extra-cellular matrix and growth factors that affect Sertoli cell functions (Maekawa et al. 
1996, Siu and Cheng 2004, Tan et al. 2005b, Verhoeven et al. 2000). Peritubular myoid cells 
might also mediate androgen action on Leydig cells (O'Shaughnessy et al. 2005). Male mice 
lacking Ar in peritubular myoid cells have reduced sperm counts, suggesting that functional 
AR in these cells is required to maintain normal function of Sertoli cells and peritubular 
myoid cells contractility (Zhang et al. 2006). 
 
3.4 Germ cells 
In the process of spermatogenesis, diploid stem cell spermatogonia develop into 
haploid spermatozoa. This development can be divided into three major phases – mitotic 
(proliferation) phase, meiotic phase, and spermiogenic (differentiation) phase (Fig. 3) (Russell 
et al. 1990).  
During the mitotic phase, spermatogonial stem cells (As) located in the periphery of 
seminiferous tubules divide and give rise to either new As cells or to interconnected A-paired 
(Apr) spermatogonia. Spermatogonial self-renewal and differentiation depend, at least in part, 
on glial cell-derived neurotrophic factor (GDNF) produced by Sertoli cells (Meng et al. 
2000). Interestingly, when cultured under appropriate conditions, spermatogonial stem cells 
from neonatal or adult mouse testis can acquire properties of embryonic stem cells (Guan et 
al. 2006, Kanatsu-Shinohara et al. 2004). Progenitors of an Apr cell connected by intercellular 
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bridges are called A-aligned (Aal) spermatogonia. A-aligned spermatogonia divide 
synchronously to form chains of 8, 16, and even 32 intercellular bridge-connected Aal cells. 
These cells differentiate into A1 spermatogonia that undergo subsequent mitotic divisions and 
give rise to A2, A3, A4, intermediate (In), and B spermatogonia (Fig. 3) (de Rooij 2001).  
The last mitosis of B spermatogonia into preleptotene spermatocytes (Pl) marks the 
start of the meiotic phase of spermatogenesis. Preleptotene spermatocytes go through 
leptotene (L), zygotene (Z), pachytene (P), and diplotene (D) phases of the first meiotic 
prophase. The first meiotic division gives rise to secondary spermatocytes that rapidly 
undergo the second meiotic division to become haploid spermatids (Fig. 3). 
Gradual differentiation (such as formation of spermatid head, acrosome, and 
flagellum) of spermatids into fully maturated spermatozoa constitutes the last, spermiogenic 
phase of spermatogenesis. Based on the spermatid morphology, the spermiogenic phase is 
 
 
 
Fig. 3. Scheme of the spermatogenesis in the mouse seminiferous epithelium. Roman numerals indicate 
stages of the epithelial cycle. As, spermatogonial stem cells; Ap, A-paired spermatogonia; Aal, A-aligned 
spermatogonia; A1–A4, type A1–A4 spermatogonia; In, intermediate spermatogonia; B, type B 
spermatogonia; Pl, preleptotene spermatocytes; L, leptotene spermatocytes; Z, zygotene spermatocytes; P, 
pachytene spermatocytes; D, diplotene spermatocytes; m, meiotic division; 1–16, step 1–16 spermatids. 
Adapted from (de Rooij 2001, Russell et al. 1990). 
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divided into several steps (16 steps in the mouse, 19 steps in the rat) (Fig. 3) (Russell et al. 
1990). 
Spermatogenesis in the mouse initiates shortly after birth. During the prepubertal 
period, the cellular composition of the testis changes reflecting the advancement of the first 
wave of spermatogenesis. Thus, up to postnatal day 6, the principal developing germ cells 
within the seminiferous tubule are spermatogonial stem cells, A-paired, and A-aligned 
spermatogonia. Meiosis initiates around postnatal day 10 with the appearance of preleptotene 
and leptotene spermatocytes. Zygotene spermatocytes appear two days later, whereas early 
pachytene spermatocytes can be seen around postnatal day 14. At about day 18, late 
pachytene spermatocytes are first observed, and two days later round spermatids occur in 
increasing numbers, marking the onset of spermiogenesis (Bellve et al. 1977). 
 
4. The cycle of the seminiferous epithelium 
The germ cells within the seminiferous tubules are organized in cell associations 
named spermatogenesis stages. Over time, each seminiferous tubule segment cycles through 
the ordered sequence of spermatogenesis stages. There are 12 stages in the mouse cycle and 
14 stages in the rat cycle (Fig. 3, roman numerals). Particular stages have a constant cell 
composition. For example, in the mouse testis type A4 spermatogonia, early pachytene 
spermatocytes, step 1 spermatids, and step 13 spermatids always group together and thus 
constitute stage I (Fig. 3) (de Rooij 2001, Russell et al. 1990). Spermatogonial stem cells, A-
paired, and A-aligned spermatogonia are present at all spermatogenesis stages. 
 
5. Hormonal regulation of spermatogenesis 
Normal testis development and spermatogenesis require coordinated action of several 
peptide and steroid hormones, such as gonadotropin releasing hormone (GnRH), luteinizing 
hormone (LH), follicle stimulating hormone (FSH), and testosterone (T) (Fig. 4) (Holdcraft 
and Braun 2004). Hypothalamic neurons produce a decapeptide GnRH and secrete it into the 
blood in a pulsatile manner. GnRH interacts with its receptor – a member of rhodopsin-like G 
protein-coupled transmembrane receptor family – that is expressed on secretory cells in 
anterior pituitary. These cells synthesize and secrete FSH and LH in response to GnRH 
stimulation (Fig. 4) (Burns and Matzuk 2002, Jennes and Conn 1994, Rispoli and Nett 2005, 
Shacham et al. 2001). Loss of GnRH signaling in hypogonadal (hpg) mice due to mutation in 
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the Gnrh gene results in undetectable levels 
of LH and FSH. As a result, the gonads fail 
to develop postnatally and spermatogenesis 
is arrested at the pachytene spermatocyte 
stage (Cattanach et al. 1977, Mason et al. 
1986). 
FSH and LH are glycoprotein 
hormones belonging to the transforming 
growth factor β (TGFβ) superfamily. They 
share a common α-subunit, but their β-
subunits are different (Holdcraft and Braun 
2004). FSH and LH interact with the 
corresponding receptors on Sertoli and 
Leydig cells.  
FSH receptor and LH receptor are G 
protein-coupled transmembrane receptors. 
FSHR is expressed on Sertoli cells 
(Rannikko et al. 1995, Tan et al. 2005b), and 
LHR is expressed on Leydig cells (Lei et al. 
2001). In male rats, full-length FSHR 
mRNA is detected by RT-PCR in the testes 
from embryonic day 16.5 onwards, and FSH binding to testicular homogenates at embryonic 
day 17.5 detects functional FSHR on Sertoli cells (Rannikko et al. 1995). Sertoli cells respond 
to FSH stimulation by producing paracrine signals stimulating Leydig cells that, in turn, 
increase testosterone production (Lecerf et al. 1993). In rat testis, LHR mRNA expression, 
ligand binding, and LH-stimulated cAMP production appear at embryonic day 15.5. LHR 
expression is confined to fetal and adult Leydig cells (Zhang et al. 1994).  
The only indispensable function of LH in mouse is the stimulation of growth and 
maturation of adult Leydig cells (Ahtiainen et al. 2007, Huhtaniemi et al. 2006). Luteinizing 
hormone receptor knockout (LuRKO) mice are born phenotypically normal having normal 
testosterone levels (Zhang et al. 2001). However, adult Leydig cells do not differentiate in 
LuRKO mice, and therefore, testosterone levels in adult LuRKO mice are significantly 
decreased and spermatogenesis is initially arrested at the round spermatid stage (Zhang et al. 
2004). Interestingly, prepubertally initiated testosterone replacement therapy can rescue the 
 
 
 
Fig. 4. Hormonal regulation of spermatogenesis. 
GnRH, gonadotropin-releasing hormone; LH, 
luteinizing hormone; FSH, follicle-stimulating 
hormone; T, testosterone. Adapted from (Holdcraft 
and Braun 2004). 
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external male phenotype and restore full spermatogenesis, but not adult Leydig cell numbers, 
in male LuRKO mice (Pakarainen et al. 2005).  
In contrast to GnRH, testosterone, and LH, FSH is dispensable for male fertility. Male 
Fshr knockout (FSHRKO) mice are fertile albeit having a reduced number of Sertoli cells and 
lower sperm counts than corresponding wild-type mice (Abel et al. 2000, Johnston et al. 
2004).  
Adult Leydig cells produce testosterone that binds to AR in Sertoli cells, Leydig cells, 
and peritubular myoid cells (Bremner et al. 1994, Suarez-Quian et al. 1999, Tan et al. 2005b). 
AR is also expressed in the brain, in particular, in hypothalamus and pituitary neurons 
(Crocoll et al. 1998, Simerly et al. 1990). Testosterone levels are regulated via an autocrine  
feedback on the Leydig cells and an endocrine feedback on GnRH- and LH-producing cells 
(Collins et al. 2003, Holdcraft and Braun 2004). Administration of exogenous testosterone 
leads to a marked slowing in GnRH pulse frequency in men and inhibits LH and FSH release 
by a direct effect on the pituitary. The regulation of GnRH release at the hypothalamus is also 
mediated in part by aromatization of testosterone to estradiol (Amory and Bremner 2003). In 
addition, Sertoli cells express inhibins and activins – members of the TGFβ superfamily – 
that, respectively, suppress and enhance FSH production (Fig. 4) (Burns and Matzuk 2002).  
Androgen signaling is indispensable for the fetal sexual differentiation and 
spermatogenesis. Ar knockout (ARKO) mice exhibit complete androgen insensitivity 
syndrome, whereas the spermatogenesis in Sertoli cell-selective Ar knockout (SCARKO) 
mice cannot progress through meiosis (Chang et al. 2004, De Gendt et al. 2004).  
 
6. The nuclear receptor superfamily 
The nuclear receptor superfamily consists of proteins that transduce signals important 
for development, metabolic regulation, and reproduction. Analysis of the complete sequence 
of the human genome revealed the presence of 48 functional members of the nuclear receptor 
superfamily (Robinson-Rechavi et al. 2001). In addition to these 48 receptors, mice possess a 
functional farnesoid receptor β (FXRβ) and thus have 49 nuclear receptors (Escriva et al. 
2004). A recent study surveyed mRNA expression patterns of all mouse nuclear receptors in 
different tissues revealing the relationship between expression patterns and functions of 
nuclear receptors (Bookout et al. 2006). 
All nuclear receptors share a similar structural organization. They have a modular 
structure consisting of the amino-terminal domain (NTD or A/B), the DNA-binding domain 
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(DBD or C), the hinge region (or D domain), and the ligand-binding domain (LBD or E) (Fig. 
5). Some nuclear receptors also contain a carboxyl-terminal F domain (McEwan 2004).  
On the basis of sequence similarities in the DBD and LBD domains, nuclear receptors 
can be divided into six subfamilies (Escriva et al. 2004). Along with estrogen, glucocorticoid, 
mineralocorticoid, progesterone receptors, and estrogen-receptor-related orphan receptors, the 
androgen receptor belongs to the steroid receptor subfamily (Beato and Klug 2000, Escriva et 
al. 2004). 
The LBDs and especially the DBDs are conserved among the nuclear receptors, 
whereas the NTDs are variable both in amino acid sequence and in length (Kumar and 
Thompson 2003, Lavery and McEwan 2005). The AR NTD harbors an activation function 1 
(AF1) (Fig. 5) containing two discrete transactivation units, Tau1 (residues 101–370, with the 
core region at residues 173–196) and Tau5 (residues 360–528) (Callewaert et al. 2006, Jenster 
et al. 1995). When artificially separated from the LBD, the AF1 region acts as a constitutively 
active hormone-independent transcription activator. The AF1 is very strong in AR, in contract 
to most other nuclear receptors (Palvimo et al. 1993, Rundlett et al. 1990). 
 
 
 
Fig. 5. Structure and covalent modifications of human androgen receptor protein. Shaded boxes correspond 
to polyglutamine and polyglycine tracts. NTD, N-terminal domain; DBD, DNA-binding domain; H, hinge 
region; LBD, ligand-binding domain; AF1, AF2, activation function 1, 2; NLS, nuclear localization signal; 
ZFR, zinc finger region; polyQ, polyglutamine tract (residues 58–78); polyG, polyglycine tract (residues 
449–472); P, phosphorylation; Ac, acetylation; SUMO, sumoylation. Amino acid residues are numbered 
according to UniProt sequence P10275. Adapted from (Dehm and Tindall 2005). 
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Within the DBD, eight conserved cysteine residues coordinate two zinc ions and form 
two zinc finger structures arranged as perpendicular α-helixes. Nuclear receptors bind to 
DNA as homo- or heterodimers (with retinoid X receptor), or as monomers. The canonical 
receptor binding DNA sequences AGAACA or AGGTCA can be arranged as inverted repeats 
with a 3-nucleotide spacing, direct repeats with variable spacing, or as single elements 
(Escriva et al. 2004, McEwan 2004). 
The flexible hinge region links the DBD to the LBD. A ligand-dependent bipartite 
nuclear localization signal (NLS) is located between the carboxyl-terminus of the DBD and 
the hinge domain (Fig. 5) (Zhou et al. 1994).  
The LBDs of all nuclear receptors have a common overall three-dimensional structure, 
while the main structural differences are in the ligand-binding pocket (Gronemeyer et al. 
2004). These differences dictate the ligand specificity of a given receptor. The AR LBD 
contains 11 α-helixes, that are numbered according to a canonical structure of nuclear 
receptor LBD (Wurtz et al. 1996), and a highly hydrophobic ligand-binding pocket (Matias et 
al. 2000, Pereira de Jesus-Tran et al. 2006, Sack et al. 2001). The AR LBD also comprises an 
activation function 2 (AF2) region (Fig. 5). Mutations within AF2 greatly reduce ligand-
dependent transcriptional activation (Thompson et al. 2001). 
 
7. Androgen receptor 
AR is a classical steroid receptor mediating actions of male sex steroids – testosterone 
and 5α-dihydrotestosterone. AR is necessary for the normal male phenotype development and 
is essential for spermatogenesis. In mouse testis, AR protein is detected in Sertoli cells, 
Leydig cells, and peritubular myoid cells (Tan et al. 2005b). 
Mouse Ar coding region spans about 167 kb on chromosome X and comprises 8 exons 
(Faber et al. 1991) (MGI database, www.informatics.jax.org, MGI:88064). 
Mouse AR protein (UniProt database, www.ebi.uniprot.org, P19091) consists of 899 
amino acid residues and shares 97% sequence homology with rat AR and 84% with human 
AR, having identical DBD and LBD sequences (Charest et al. 1991). Human AR (UniProt, 
P10275) (Fig. 5) contains two polymorphic homopolymeric amino acid stretches in its NTD: 
the polyglutamine tract, which is 11–37 residues long, and the polyglycine tract, which spans 
12–29 residues (Gottlieb et al. 2004). A polyglutamine tract expansion of more than 38 
residues causes hormone-dependent dysfunction and degeneration of motor neurons in males 
leading to spinobulbar muscular atrophy (SBMA, or Kennedy’s disease) – an adult-onset 
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motor neuropathy causing progressive muscle wasting and weakness (Gottlieb et al. 2004, La 
Spada et al. 1991). Recently, a knock-in mouse model of this disease has been described, 
where an expanded polyglutamine tract (113 CAGs) from the human AR was introduced into 
the mouse Ar gene. Similar to Kennedy’s disease patients, these mice developed hormone and 
glutamine length-dependent neuromuscular weakness, partial androgen insensitivity, and 
testicular pathologies (Yu et al. 2006a, Yu et al. 2006b).  
In testicular feminized (Tfm) mice, a spontaneously occurring frameshift mutation in 
the AR NTD results in a premature termination of AR translation at amino acid residue 412 
(Charest et al. 1991, He et al. 1991). The loss of AR activity in these mice leads to total 
androgen insensitivity (Bardin et al. 1973, Lyon and Hawkes 1970). Several other mouse 
models have been created, such as total (ARKO) or Sertoli cell-selective (SCARKO) Ar 
knockout (Chang et al. 2004, De Gendt et al. 2004, Sato et al. 2004, Yeh et al. 2002). Male 
Tfm and ARKO mice are externally feminized, having a blunt-end vagina and a clitoral-like 
phallus (Bardin et al. 1973, Sato et al. 2004, Yeh et al. 2002). Tfm and ARKO males lack 
seminal vesicles, vas deferens, epididymis, and prostate; however, they have small 
undescended testes where spermatogenesis is arrested at the pachytene spermatocyte stage 
(Blackburn et al. 1973, Yeh et al. 2002). In addition, ARKO males exhibit reduced heart-to-
body weight ratio (Ikeda et al. 2005). Male-typical behaviors in Tfm and ARKO male mice 
are impaired whereas female-typical behaviors are absent (Lyon and Hawkes 1970, Sato et al. 
2004). ARKO females appear normal, but have reduced fertility and defective 
folliculogenesis (Hu et al. 2004).  
In humans, loss-of-function mutations in the AR gene result in androgen insensitivity 
disorders of different severity, whereas activation mutations frequently lead to development 
and progression of prostate cancer (Abate-Shen and Shen 2000, Hyytinen et al. 2002, Linja 
and Visakorpi 2004, Quigley et al. 1995, Thompson et al. 2003). 
 
8. Androgen receptor in transcription control 
Unliganded AR resides in the cytoplasm forming a complex with chaperones such as 
Hsp70, Hsp90, and FKBP52 that maintain AR in a conformation able to bind hormone (Fig. 
6) (Cheung-Flynn et al. 2005, Gobinet et al. 2002). Due to its lipophilic nature, free 
testosterone can diffuse through the cellular membrane (Mendel 1989); however, when bound 
to sex hormone-binding globulin, testosterone may also be internalized through endocytosis 
(Hammes et al. 2005). Intracellular testosterone can bind AR directly, or it can be reduced to 
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5α-dihydrotestosterone (DHT) by 5α-reductase (5α-R) (Fig. 6). Upon hormone binding, the 
AR LBD changes its conformation so that helix 12 folds over the ligand-binding pocket 
(Gobinet et al. 2002). Interaction between AF2 region and FXXLF motif in the amino-
terminus of AR further stabilize ligand-bound conformation (He et al. 2006, Heinlein and 
Chang 2002, Hsu et al. 2005). Binding of the ligand to AR triggers dissociation of 
chaperones, phosphorylation, exposure of two zinc fingers in the DBD, and unmasking of 
dimerization motifs and the NLS (Gobinet et al. 2002, Gottlieb et al. 2004). Importin-α 
recognizes the unmasked NLS and, together with importin-β, mediates translocation of 
liganded AR through the nuclear-pore complex (Black and Paschal 2004).  
Upon nuclear translocation, AR recognizes and binds to androgen response elements 
(AREs) in DNA, and interacts with the basal transcription machinery. Numerous coregulatory 
proteins modulate AR activity (Gelmann 2002, Heinlein and Chang 2002, Jänne et al. 2000, 
Kang et al. 2004, Lee and Chang 2003, Lee et al. 2001, Lee and Kraus 2001, Lonard and 
O'Malley B 2006). Interestingly, different coregulators interact with agonist (T, DHT)-bound 
or antagonist (casodex)-bound AR (Kang et al. 2004, Shang et al. 2002). 
Agonist-bound AR interacts with proteins of p160 family that includes histone 
acetyltransferases SRC-1 (also called NCoA1) and SRC-3 (also called p/CIP, ACTR, AIB1, 
RAC3, or TRAM1) (Aranda and Pascual 2001, Heinlein and Chang 2002). Together with the 
third p160 family member SRC-2 (also called TIF2, GRIP1, or NCoA2), these proteins 
interact with acetyltransferases CBP (CREB binding protein), p300 (highly related to CBP), 
and PCAF (p300/CBP-associated factor) (Fig. 6) (Black and Paschal 2004, Heinlein and 
Chang 2002, Shang et al. 2002). In addition, AR interacts with histone demethylases LSD1 
and JHDM2A (Metzger et al. 2005, Yamane et al. 2006) and, through BAF57, with ATP-
dependent chromatin remodeling complex SWI/SNF (Fig. 6) (Link et al. 2005). As we will 
discuss later, a core component of SWI/SNF complex is an SNF2-family ATPase – either 
BRM or BRG1. Interestingly, there seems to be a preference for BRM over BRG1 as the core 
ATPase for AR activity (Marshall et al. 2003). Chromatin remodeling by ATP-dependent 
remodeling complexes, histone demethylation by demethylases, and histone acetylation by the 
histone acetyltransferases collectively serve to loosen histone-DNA interactions and facilitate 
AR binding to AREs. Canonical ARE consists of two half-sites AGAACA arranged as 
inverted repeats with a 3-nucleotide spacing (Gobinet et al. 2002). However, recent chromatin 
immunoprecipitation experiments mapping AR binding sites on chromosomes 21 and 22 
demonstrate that only 10% of binding sites contain these canonical AREs. In many cases the 
AR half-site was found in association with FoxA1, C/EBPA, GATA, or Oct1 binding motifs, 
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suggesting that AR collaborates with other DNA-binding transcription factors to regulate 
gene transcription (Qianben Wang and Olli A. Jänne, personal communications). AR binding 
to DNA changes the conformation of the NTD and influences its interaction with AR 
coregulators (Brodie and McEwan 2005). Thyroid hormone receptor-associated protein 
(TRAP)-Mediator complex interacts with AR and facilitates recruitment of RNA polymerase 
II (Wang et al. 2002). In addition, direct interactions with TATA-binding protein (TBP), 
TFIIB, and RNA polymerase II bridge AR complex to the basal transcriptional machinery 
(Fig. 6) (Black and Paschal 2004, Heinlein and Chang 2002, Shang et al. 2002). Direct 
interaction of AR amino-terminus with TFIIF further stabilizes the transcription activation 
complex (McEwan and Gustafsson 1997). Recent report shows that transcriptional repressors 
NCoR and SMRT can actively compete with coactivators for binding to agonist-bound AR 
and attenuate activation of AR target genes (Fig. 6) (Yoon and Wong 2006).  
Interestingly, antagonist-bound AR is loaded onto promoter of the androgen-
responsive PSA gene approximately as efficiently as the agonist-bound receptor (Kang et al. 
2002). Antagonist-bound AR interacts with corepressors NCoR and SMRT that form 
 
 
 
Fig. 6. Transcriptional regulation by androgen receptor. DHT, dihydrotestosterone; HSP, heat shock proteins; 
5α-R, 5α-reductase; ARE, androgen response element; pol II, RNA polymerase II; HDACs, histone 
deacetylases; P, phosphorylation; Ac, acetylation. Adapted from (Dehm and Tindall 2005, Shang et al. 2002). 
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complexes with histone deacetylases mediating chromatin condensation and repression of 
target gene transcription (Kang et al. 2004, Yoon and Wong 2006). In response to 
proinflammatory cytokines, such as interleukin 1β, NCoR complex can be dismissed from 
antagonist-bound AR leaving the receptor free to interact with coactivators and activate 
transcription of target genes (Baek et al. 2006, Zhu et al. 2006). 
The mechanism outlined above is by no means complete, as numerous other AR 
coregulators have been identified. A steadily growing database of putative nuclear receptor 
coregulators – the Nuclear Receptor Signaling Atlas (NURSA) – is available online 
(www.nursa.com), as well as the list of AR coregulators 
(androgendb.mcgill.ca/ARinteract.pdf). These coregulators modulate AR-dependent 
regulation either by interacting with DNA-bound AR (type I coregulators) or by stabilizing 
ligand-bound receptor conformation, influence AR protein stability and subcellular 
distribution (type II coregulators) (Heinlein and Chang 2002). AR, its coregulators, and 
components of the RNA polymerase II complex are also subject to different covalent 
modifications including sumoylation, acetylation, and phosphorylation (Fig. 5) (Fu et al. 
2000, Gioeli et al. 2002, Poukka et al. 2000). These modifications are mediated by SUMO-1 
ligases such as the PIAS family proteins, acetyltransferases p300, CBP, PCAF, androgen 
receptor-interacting nuclear kinase (ANPK), MAPK family kinases, and other coregulators 
(Dehm and Tindall 2005, Fu et al. 2000, Heinlein and Chang 2002, Kotaja et al. 2002, 
Moilanen et al. 1998a). SUMO-1 ligases PIAS1 and ARIP3/PIASxα enhance sumoylation of 
AR and repress AR-dependent transcription (Nishida and Yasuda 2002, Wu and Mo 2007). 
Recently, a small carboxyl-terminal domain phosphatase 2 (SCP2) was found to interact with 
AR, possibly acting as a “molecular brake” in AR-dependent transcription (Thompson et al. 
2006). Covalent modifications influence AR transactivation and provide a mechanism for 
cross-talk between androgen and growth factor signaling (Dehm and Tindall 2005, Heinlein 
and Chang 2002, Heinlein and Chang 2004). Finally, some nuclear receptor coregulators are 
involved in splicing and thus can spatially and temporally coordinate transcription and RNA 
maturation (Auboeuf et al. 2005). 
AR-dependent gene regulation is a very dynamic process. AR is highly mobile in the 
nucleus, and agonist- and antagonist-bound receptors have distinct nuclear localization 
patterns (Black and Paschal 2004, Karvonen et al. 2002). Chromatin immunoprecipitation 
assays have shown that AR, coregulators, and RNA polymerase II are recruited to promoters 
and enhancers of AR target genes (such as PSA and KLK2) in transient and cyclic fashion 
(Kang et al. 2004, Kang et al. 2002, Shang et al. 2002, Thompson et al. 2006). This dynamic 
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pattern appears to be critical for AR-dependent transcriptional regulation and depends on the 
proteasome function (Dennis and O'Malley 2005). Evidence that AR interacts with E3 
ubiquitin ligase SNURF (also called RNP4) (Häkli et al. 2004, Moilanen et al. 1998b) and is 
subject to ubiquitination (Tian et al. 2006) further supports the importance of the proteasome 
function in AR-dependent transactivation.  
 
9. The SNF2 protein family 
9.1 Overview of the SNF2 family 
Yeast sucrose non-fermenting protein 2 (SNF2) – the founding member of the SNF2 
protein family – was first described in a study analyzing Saccharomyces cerevisiae mutants 
having defects in sucrose or raffinose fermentation (Neigeborn and Carlson 1984). The 
characteristic feature of the SNF2 family is the presence of a highly conserved domain of 
about 400 amino acid residues that is involved in ATP binding and hydrolysis (Eisen et al. 
1995). Bioinformatic analyses have revealed the presence of 17 and 21 SNF2 family members 
in S. cerevisae and Caenorhabditis elegans genomes, and 29 SNF2 family members in the 
human genome (Chervitz et al. 1998, Linder et al. 2004). 
Further amino acid sequence analysis of the ATPase domains divides the human SNF2 
family into two major groups (Fig. 7) (Flaus et al. 2006, Linder et al. 2004). The first group 
includes proteins, such as BRM (also called SNF2α or SMARCA2), BRG1 (also called 
SNF2β or SMARCA4), SNF2H (also called SMARCA5), chromodomain (CHD) proteins, 
and INOC1 (also called INO80) that utilize the energy of ATP hydrolysis to loosen the 
contacts between DNA and histone octamers. Parameters of ATPase reaction and functional 
differences among these proteins have been relatively well characterized (Aalfs et al. 2001, 
Boyer et al. 2000, Fan et al. 2003). These proteins serve as the core ATPase components of 
large multiprotein ATP-dependent chromatin remodeling complexes, such as SWI/SNF, 
ISWI, NuRD, and INO80 (Jones et al. 2000, Kingston and Narlikar 1999, Roberts and Orkin 
2004, Shen et al. 2000, Vignali et al. 2000) that facilitate or inhibit DNA access for 
transcriptional factors and/or histone-modifying enzymes (Lusser and Kadonaga 2003) and 
serve as coregulators for numerous transcription factors, including nuclear receptors 
(Belandia and Parker 2003, Lemon and Freedman 1999). Human BRM protein can also 
associate with several components of the spliceosome and regulate inclusion of alternative 
exons in the mRNA of several genes. Interestingly, the chromatin-remodeling activity of 
BRM is not required for its action on splicing (Batsche et al. 2006). The first group of the 
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SNF2 family also includes HELLS (also called LSH or PASG) – an important factor in 
determining DNA methylation that is crucial for heterochromatin organization (Dennis et al. 
2001).  
The second major group of the SNF2 family includes proteins, such as the α-
thalassemia mental retardation X-linked protein (ATRX), RAD54, RAD26 (also called 
ERCC6), and TTF2 (also called LODESTAR), that are involved in DNA excision repair, 
homologous recombination, or termination of transcription (Allard et al. 2004, Bugreev et al. 
2006, Kanaar et al. 1996, Liu et al. 1998, van der Horst et al. 1997). In the presence of 
RAD51, RAD54 displays an ATP-dependent chromatin remodeling activity (Alexeev et al. 
2003, Alexiadis and Kadonaga 2002). Similarly, an ATP-dependent chromatin remodeling 
complex consisting of ATRX and death domain-associated protein (DAXX) have been 
described (Tang et al. 2004a, Xue et al. 2003). However, both ATRX and RAD54 are not 
active chromatin remodelers, and their complexes differ from SWI/SNF and NuRD in 
mononucleosome remodeling activities (Xue et al. 2003). Instead of being active chromatin 
remodeler, RAD54 catalyzes D-loop formation during recombination and promotes 
homologous DNA pairing and branch migration of Holliday junctions during DNA repair 
process (Bugreev et al. 2006, Jaskelioff et al. 2003, Petukhova et al. 1998). ATPase domain of 
ARIP4 has a high sequence similarity with the ATPase domain of ATRX protein (Fig. 7) 
 
 
 
Fig. 7. Overview of the human SNF2 protein family. The tree results from the alignment of amino acid 
sequences of the SNF2 ATPase domains. Adapted from (Linder et al. 2004). 
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(Linder et al. 2004). Based on the ATPase domain homology, ARIP4 together with RAD54 
and ATRX comprise RAD54-like subfamily of SNF2 protein family (Flaus et al. 2006).  
Thus, the two groups of the SNF2 family proteins reflect functional differences 
between the SNF2 family members. The proteins belonging to the first group are “true” ATP-
dependent chromatin remodelers involved in transcriptional regulation, whereas the proteins 
from the second group, despite exhibiting some chromatin remodeling activity, are generally 
involved in DNA repair and homologous recombination (Linder et al. 2004). 
 
9.2 The role of SNF2-family proteins in apoptosis and cell proliferation 
 Apoptosis is an essential process required for embryonic development and 
maintenance of normal cellular homeostasis. Numerous pathological conditions, such as 
cancer, autoimmunity, or degenerative disorders, can arise as a result of defects in apoptosis 
(Adams 2003, Danial and Korsmeyer 2004).  
Caspases (cysteine-containing proteases that cleave aspartic acid-containing protein 
motifs) play a central role in apoptosis by cleaving several hundred cellular substrates 
(Thornberry and Lazebnik 1998). Caspases are produced as inactive zymogens that are 
activated in response to apoptotic stimuli, such as activation of cell death receptors on the cell 
surface or various forms of stress (intracellular damage or lack of growth factor stimulation). 
After apoptosis activation, upstream (initiator) caspases (caspase-8 in death receptor pathway 
or caspase-9 in stress pathway) undergo dimerization and autocatalytic cleavage. Activated 
initiator caspases cleave and activate the downstream (effector) caspases, such as caspase-3 
and caspase-7, that initiate general proteolysis (Adams 2003). 
The central role in the control of apoptosis belongs to the proteins of Bcl-2 family that 
includes several pro-apoptotic (such as Bax, Bad, and Bak) and pro-survival (such as Bcl-2 
and Bcl-xL) factors (Adams 2003, Shibue and Taniguchi 2006). The pro-survival factor Bcl-2 
prevents Bax/Bak activation under normal conditions. In response to apoptotic stimuli, 
phosphorylated Bad binds Bcl-2 and prevents it from interacting with Bax/Bak. In turn, Bax 
and Bak promote permeabilization of the outer mitochondrial membrane leading to the 
cytosolic release of other pro-apoptotic proteins such as cytochrome c, Smac/DIABLO and 
HtrA2/Omi, that both initiate and promote caspase activation (Shibue and Taniguchi 2006). 
Other apoptosis control factors include inhibitors of apoptosis (IAPs) that directly bind and 
inhibit caspase-3, -7, and -9 (Danial and Korsmeyer 2004). 
Several reports suggest the involvement of the SNF2 family proteins in regulation of 
apoptosis and cell proliferation. Embryos lacking functional Brg1 or Snf2h die before the 
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implantation stage, some time between E3.5 and E6.5, due to defects in cell proliferation 
(Bultman et al. 2000, Stopka and Skoultchi 2003). In contrast, Brm knockout mice develop 
normally, probably due to the compensation provided by Brg1. However, fibroblasts derived 
from Brm null mice exhibit proliferation defects (Reyes et al. 1998). Mice lacking Hells 
exhibit abnormal lymphoid development and renal defects, and die within a few hours after 
birth (Geiman et al. 2001). ATRX-Daxx complex appears to be involved in apoptosis 
regulation and in mammalian sex differentiation (Tang et al. 2004a, Tang et al. 2004b, Xue et 
al. 2003). Deletion of the Atrx gene causes early embryonic lethality and conditional knockout 
of Atrx in forebrain results in marked increase in neuronal apoptosis, indicating that ATRX is 
a critical mediator of cell survival during early development and neuronal differentiation 
(Berube et al. 2005). In contrast, mice lacking Rad54 appear normal despite reduced 
resistance to ionizing radiation and reduced homologous recombination in Rad54–/– ES cells 
(Essers et al. 1997). 
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AIMS OF THE STUDY 
The subject of this research project is the androgen receptor-interacting protein 4 (ARIP4; 
the official mouse gene name is Rad54 like 2 (Rad54l2); also called Srisnf2l). At the time this 
project was initiated, there was evidence that ARIP4 interacts with AR in yeast and 
mammalian two-hybrid assays and acts as an AR coregulator in reporter gene assays. 
Analysis of ARIP4 sequence revealed a region of high similarity with the ATPase domain of 
SNF2 family of chromatin remodeling proteins. Northern blot analysis indicated that ARIP4 
mRNA is virtually ubiquitous in adult rat and mouse tissues.  
 
The specific aims of this project are: 
 
• To study ARIP4 interaction with AR in physiological conditions 
• To investigate the role of ARIP4 as a possible AR-specific chromatin remodeler 
• To characterize the biochemical properties of ARIP4 
• To elucidate AR-dependent and AR-independent functions of ARIP4 by studying 
Arip4 knockout mice 
• To analyze ARIP4 expression and regulation during postnatal testis development and 
spermatogenesis 
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METHODS 
 Detailed descriptions of the materials and methods used in this study can be found in 
the original publications (I–IV) as shown in Table 2. 
 
 
Table 2. Methods used in this study 
Method 
Original 
publication 
Plasmid construction and recombinant DNA technology I, II 
Bacterial, insect, and mammalian cell culture I, II 
Transfections and reporter gene assays I, II 
SDS-PAGE and immunoblotting I, II 
Immunoprecipitation I, II 
Production of recombinant proteins in bacterial, mammalian, and 
insect cells 
I, II 
ATPase activity assays I, II 
In vitro assays of protein-protein and protein-DNA interactions I, II 
Nucleic acid purification I, II, III, IV 
Histone octamer purification and nucleosome reconstitution II 
Immunohistochemistry III, IV 
Microarray data analysis IV 
In situ hybridization and Northern blotting III 
Quantitative RT-PCR III, IV 
Embryo whole-mount X-gal staining IV 
Isolation and culture of mouse embryonic fibroblasts IV 
Flow cytometry and cell proliferation analysis IV 
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RESULTS AND DISCUSSION 
1. ARIP4 is an active DNA-dependent ATPase of the SNF2 family (I, II, III) 
In order to identify novel coregulators interacting with the DBD of AR, a yeast two-
hybrid system was utilized. A fusion between LexA protein and the zinc finger region (ZFR; 
residues 554–644, Fig. 5) of human AR served as a bait to screen an E10.5 mouse embryo 
cDNA library fused to the VP16 activation domain. The positive clones were tested against 
several control plasmids to eliminate nonspecific interactions, and the remaining true positive 
clones were sequenced. This assay identified several potential AR coregulators, including 
SNURF, ANPK, and ARIP3/PIASxα (Moilanen et al. 1998a, Moilanen et al. 1998b, 
Moilanen et al. 1999). Some positive clones contained cDNA fragments of a previously 
uncharacterized protein that was named androgen receptor-interacting protein 4 (ARIP4). 
Subsequently, screening of an E11.5 mouse embryo cDNA library with a radiolabeled ARIP4 
cDNA fragment corresponding to amino acid residues 91–230 revealed a full-length ARIP4 
cDNA. 
The complete mouse genome sequence (Waterston et al. 2002) greatly simplified the 
analysis of Arip4 gene structure. The Arip4 coding region spans about 97 kb on chromosome 
9 and contains 22 exons (MGI database, www.informatics.jax.org, MGI:1933196). ARIP4 
mRNA is approximately 10 kb in size and is relatively ubiquitously expressed in rat and 
mouse tissues, with the highest expression levels in liver, kidney, and testis. 
 ARIP4 is 1466 amino acid residues long protein that contains a region with sequence 
homology to the ATPase domain of the SNF2 protein family (residues 300–880, Fig. 9, 10). 
On the basis of its ATPase domain sequence, ARIP4 classifies into the second group of the 
SNF2 protein family with ATRX being its closest homolog in human and mouse (Fig. 7) 
(Linder et al. 2004). In contrast, the amino- and carboxyl-terminal regions of ARIP4 have no 
similarity to any currently known conserved protein domains. ARIP4 protein has orthologs in 
rat (98% sequence homology), human (96%), and dog (95%), but not in yeast. 
 Available data indicate that human ARIP4 (UniGene database, Hs.105399) is 
ubiquitously expressed in adult human tissues. ARIP4 ESTs are also found in embryo, fetus, 
and juvenile (less than 17 years old) humans, but, interestingly, not in neonates and infants 
(less than 3 years old). In addition, ARIP4 expression is detected in numerous cancers, 
including retinoblastoma, kidney, germ cell, and ovarian tumors 
(www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.105399). ARIP4 mRNA 
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levels are increased in advanced stages of prostate cancer (Linja et al. 2004). However, the 
role of ARIP4 in cancer progression remains to be elucidated. Yeast two-hybrid screens 
identified mouse ARIP4 protein as interaction partner for a dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 1A (Dyrk1A) (Sitz et al. 2004) and carboxyl-terminal 
binding protein 1 (CtBP1) (Qinghong Zhang, personal communication). Apart from these data 
and our results presented in this work, not much is known about ARIP4 and its orthologs.  
Analysis of ARIP4 protein sequence for the presence of short conserved motifs 
identified three bipartite nuclear localization signals, several sumoylation and phosphorylation 
sites, and three LXXLL motifs known to mediate interactions with nuclear receptors 
(summarized in Fig. 10) (Balla et al. 2006, Heery et al. 1997).  
The sequence of ARIP4 suggests that there is a DNA-dependent ATPase activity in 
the protein. Indeed, purified ARIP4 binds ATP and has intrinsic ATPase activity that depends 
on the presence of double- or single-stranded DNA in the reaction mixture. Mutations within 
the putative catalytic centre (Lys-310 to Ala (K310A), and Asp-462/Glu-463 to Ala/Ala 
(DE462AA)) result in loss of the ATPase activity. In contrast, all other ARIP4 point mutants 
 
 
 
Fig. 8. ATPase activity of ARIP4 deletion mutants. Wild-type ARIP4 or indicated mutants were produced 
in COS-1 cells. ATPase activity in the presence or in the absence of 80 nM double-stranded DNA was 
assayed as described in (II). ATPase reaction was stopped after 60 min incubation at 30°C. One-microliter 
samples were spotted onto a poly(ethyleneimine) thin-layer plate that was developed in 1 M LiCl/1 M 
formic acid to resolve [32P]Pi from [γ-32P]ATP. The plate was subjected to autoradiography. The amount of 
released [32P]Pi was quantified by scanning autoradiograms using Kodak Image station 440CF (Eastman 
Kodak, Rochester, NY). The values are shown relative to that of wild-type ARIP4 in the presence of 
double-stranded DNA (=100). Each bar represents the mean ± standard deviation values for three 
independent experiments. 
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except sumoylation-deficient ARIP4(6K→6R) have ATPase activities comparable to wild-
type ARIP4 (Table 3). Carboxyl-terminal truncation of ARIP4 (ARIP4(1–1314)) does not 
affect enzymatic activity whereas ARIP4(1–889), despite having an intact ATPase domain, 
loses the ability to hydrolyze ATP. Similarly, ARIP4(1–620) and ARIP4(1–276) cannot 
hydrolyze ATP (Fig. 8). As described below, ARIP4(6K→6R), ARIP4(1–889), and shorter 
amino-terminal ARIP4 fragments cannot bind DNA in EMSA experiments (Fig. 9 and Table 
3). Thus, the ability to bind DNA appears to be crucial for the ATPase activity of ARIP4. 
By titrating the concentration of one reaction component and monitoring ADP release 
rate in a fluorometric ATPase assay, we estimated the kinetic parameters of ATP hydrolysis 
catalyzed by ARIP4. Estimated Km for dsDNA and Km for ATP are similar to those of BRG1 
and SNF2h proteins (Aalfs et al. 2001). However, the catalytic activity of wild-type ARIP4 
(being 600 ± 100 nmol ADP released per minute per milligram ARIP4 or approximately 120 
molecules of ATP hydrolyzed by protein molecule per minute) is some 10 times lower than 
that of other ATP-dependent chromatin remodeling enzymes, that typically hydrolyze about 
1000 ATP molecules per minute (Peterson 2000). 
 
2. ARIP4 interacts with AR and binds to DNA (I, II) 
The initial yeast two-hybrid screen identified an AR interaction domain residing 
within residues 91–230 of ARIP4. In yeast, the ARIP4 fragment spanning residues 86–227 
(ARIP4(86–227)) interacts with the AR ZFR. However, deletion of 20 hinge region residues 
from the AR ZFR markedly weakens the ARIP4-AR interaction. The ARIP4(86–227) 
fragment also exhibits a weak interaction with the AR hinge-LBD region (residues 624–919). 
Both in yeast and in mammalian two-hybrid assays, ARIP4(86–227) exhibits strong 
testosterone-dependent interaction with full-length AR. However, when coexpressed with AR 
in mammalian cells, ARIP4(1–620) but not ARIP4(1–276) coimmunoprecipitates with the 
receptor. Interestingly, both ARIP4(278–1466) and ARIP4(278–1314) are capable of binding 
to AR ZFR in GST pull-down experiments (Fig. 9), possibly interacting with AR through 
LXXLL motifs that are known to mediate nuclear receptor binding (Heery et al. 1997). 
Finally, the interaction of ARIP4 with AR does not depend on ARIP4 ATPase activity or 
ability to bind DNA, as both ATPase-deficient mutant ARIP4-K310A and DNA binding-
deficient mutant ARIP4(1–620) can recognize AR in coimmunoprecipitation experiments. 
Taken together, these results suggest a complex nature of ARIP4 – AR interaction that 
apparently involves ARIP4 region (86–227) and LXXLL motifs (Fig. 10). 
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Wild-type ARIP4, ARIP4(1–1314), and all tested point mutants except 
ARIP4(6K→6R) can bind to a 32-bp DNA fragment in EMSA experiments, whereas 
 
 
 
Fig. 9. ARIP4 deletion mutants and summary of their properties. ATPase domain, LXXLL motifs, and residues 
mutated to study ARIP4 ATPase activity (Lys-310, Asp-462/Glu-463) and sumoylation (Lys-361, Lys-573, 
Lys-664, Lys-935, Lys-961, and Lys-1013) are shown. Shaded boxes correspond to conserved motifs in the 
SNF2 ATPase domain. AR binding was assayed by coimmunoprecipitation (a), yeast two-hybrid (b), or GST 
pull-down (c). As marked by +/–, wild-type ARIP4 enhances AR activity on the minimal (ARE4-tk) promoter 
and attenuates AR activity on a more complex (probasin) promoter. 
 
Table 3. ARIP4 point mutants and summary of their properties 
Mutant 
ATPase 
activity 
DNA binding 
AR dependent 
transactivation 
(ARE4-tk) 
Sumoylation 
Wild-type + + + + 
K310A – + repression + 
DE462AA –  repression  
K573R +  + + 
K664R +  + + 
K935R + + + + 
K1013R + + + + 
KK361/961RR +  + + 
KK573/964RR +  + + 
4K→4R +  + + 
5K→5R + + + reduced 
6K→6R – – no effect – 
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ARIP4(6K→6R), ARIP4(1–889), and shorter amino-terminal ARIP4 fragments fail to bind 
DNA (Fig. 9 and Table 3). These results may suggest that the ARIP4 DNA binding domain 
localizes within residues 890–1314. We could not, however, directly demonstrate DNA 
binding of ARIP4(890–1316) or any other ARIP4 amino-terminal deletion mutant, including 
the mutants having amino-terminal region of ARIP4 (residues 1–278) fused to putative DNA 
binding region (residues 890–1206 or 890–1309). Thus, the presence of the ATPase domain 
(residues 300–880) within ARIP4 seems to be important for the correct folding of the DNA-
binding domain. The combination of lysine mutations in ARIP4(6K→6R) may result in 
misfolding of the ARIP4 DNA binding domain, as three of the six lysine residues mutated in 
ARIP4(6K→6R) (Lys-935, Lys-961, and Lys-1013) are located within the putative DNA 
binding region.  
Finally, we have found no nucleotide sequence preference for the DNA binding of 
ARIP4, as ARIP4 interacted with all DNA oligonucleotides tested by EMSA, and poly(dI-
dC)•(dI-dC) efficiently competes with DNA for ARIP4 binding. DNA binding does not 
depend on ARIP4 ATPase activity, as ATPase-deficient mutant ARIP4-K310A binds DNA 
similarly to wild-type ARIP4. 
 
3. ARIP4 is an AR coregulator (I, II, III) 
To study the effect of ARIP4 on AR-dependent transactivation, we performed several 
transient transfection assays in mammalian cells using reporter constructs driven by different 
promoters. Coexpression of wild-type ARIP4 with AR results in a two- to three-fold increase 
in AR transcriptional activity on a minimal (ARE4-tk) promoter. This effect appears to be 
AR-specific, as ARIP4 fails to activate glucocorticoid receptor (GR) or progesterone receptor 
(PR) function on the same promoter. However, ARIP4 is capable of enhancing both AR- and 
GR-dependent transactivation of the MMTV promoter-driven reporter gene (Sitz et al. 2004). 
Interestingly, the carboxyl-terminal truncation mutant ARIP4(1–1314), despite retaining wild-
type ATPase activity and ability to bind AR and DNA, is significantly less active in AR 
coactivation. Apparently, ARIP4 carboxyl-terminal region mediates interactions with other 
coactivators. Indeed, Dyrk1A – a serine/threonine kinase involved in neuronal development 
and mental retardation in Down syndrome patients – interacts with residues 1078–1466 of 
ARIP4 (Fig. 10). ARIP4 cooperates with Dyrk1A to modulate both AR- and GR-mediated 
transactivation in adult mouse brain, however, this effect is not mediated by phosphorylation 
of ARIP4 by Dyrk1A (Sitz et al. 2004). ARIP4 and Dyrk1A are coexpressed and colocalized 
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in neurons of the hippocampus (Sitz et al. 2004), where AR is also expressed (Kerr et al. 
1995). The hippocampus plays a critical role in learning and memory, and it is the most 
clearly affected region of the brain in Down syndrome patients (Nadel 2003). Thus, by 
modulating AR activity in hippocampal neurons, ARIP4 may play a role in physiological 
processes in mammalian brain. Interestingly, mutations in a close ARIP4 homolog, ATRX, 
cause ATRX syndrome with mental retardation (Gibbons et al. 1995). 
ATPase-deficient mutants of ARIP4 are unable to act as AR coactivators. Instead, they 
behave as trans-dominant negative regulators of AR function, probably by sequestering AR 
interaction partners. In contrast, mutations of potential sumoylation sites do not significantly 
affect ARIP4 coactivator activity. However, as expected, the ATPase- and sumoylation-
deficient mutant ARIP4(6K→6K) unable to bind DNA also loses its ability to act as an AR 
coactivator (Table 3). 
Surprisingly, ARIP4 fails to activate AR function on the more complex AR-dependent 
probasin promoter in transient transfection assay. In fact, wild-type ARIP4 and ATPase-
deficient mutants attenuate AR-dependent transactivation. Thus, in transient transfection 
assays ARIP4 behaves as AR coactivator on a minimal promoter and as a modest AR 
corepressor on a more complex probasin promoter. This is not a totally unexpected behavior 
for a SNF2 family protein, as proteins of this family are known to act as promoter-specific 
transcriptional activators or repressors (Kingston and Narlikar 1999, Tyler and Kadonaga 
1999). For example, the yeast SWI/SNF complex exhibits promoter specificity by down-
regulating some genes while up-regulating other ones (Holstege et al. 1998).  
Under physiological conditions, gene transcription occurs in the context of chromatin. 
Therefore, an assay using cells that have a stably integrated (“chromatinized”) reporter gene 
approximates much better AR-dependent transactivation in vivo. A recent report shows that, 
in contrast to results from transient transfection assays, N/C interaction-defective AR mutants 
are inactive in regulating transcription of stably integrated reporter genes (Li et al. 2006). If 
we hypothesize that ARIP4 alters chromatin organization, ARIP4 coregulator properties must 
be studied on the chromatin-assembled reporter gene. Therefore, to investigate the properties 
of ARIP4 as an AR coregulator, we studied the effects of ectopic ARIP4 expression in a 
prostate cancer cell line that has been stably transfected with probasin promoter-driven 
reporter gene. In this system, wild-type ARIP4 elicits about a 1.5-fold increase in AR-
dependent transactivation, whereas the ATPase-deficient mutants have no effect on AR 
function. 
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Additional evidence for the role of ARIP4 as an AR coregulator comes from 
heterozygous Arip4+/– mice. In Arip4+/– testis the mRNA level of a Sertoli cell-specific 
androgen-dependent protein Rhox5 (also called Pem) (Lindsey and Wilkinson 1996) is 
reduced to approximately 80% of that in wild-type controls. Similarly, mRNA level of Eppin 
(epididymal protease inhibitor) (Denolet et al. 2006, Sivashanmugam et al. 2003) is slightly 
reduced in Arip4+/– testis. 
Taken together, these results have indicated that ARIP4 can function as an AR 
coregulator both in transient transfection assays and, more importantly, in assays using cells 
that have a stably integrated reporter gene. Moreover, we demonstrate that ARIP4 is required 
for androgen-dependent regulation of at least some genes in vivo. 
 
4. ARIP4 binds, but does not remodel, reconstituted mononucleosomes (I, 
II) 
What are the molecular mechanisms of ARIP4 action and, in particular, how does 
ARIP4 use the energy generated as a consequence of ATP hydrolysis? Several SNF2 family 
members use ATP hydrolysis energy to elicit superhelical torsion within linear DNA 
fragments. This is suggested to be the primary biomechanical activity shared by all ATP-
dependent chromatin remodeling proteins (Havas et al. 2000). We have demonstrated that 
wild-type ARIP4, but not ATPase-deficient mutant ARIP4-K310A, can also generate a 
negative supercoiling within a linear DNA molecule. 
To test whether ARIP4 exhibits mononucleosome remodeling activity, we utilized the 
restriction enzyme accessibility (REA) assay. For this assay, we used purified histone 
octamers to reconstitute mononucleosomes on 32P-labeled DNA fragments bearing a 
nucleosome positioning sequence and a Pst I restriction site. REA assays with the ATPase-
dependent chromatin remodelers BRG1 and SNF2h (Fan et al. 2003) and our REA assay with 
yeast RSC (Remodels the Structure of Chromatin) complex clearly demonstrate that the 
restriction enzyme can gain access to its recognition sequence only in the presence of 
chromatin remodeling activity. Should ARIP4 be a chromatin remodeler, Pst I would digest 
DNA at the cognate recognition site in the presence of ARIP4 and ATP. Under our 
experimental conditions, Pst I could not digest either intact mononucleosomes or those 
preincubated with ARIP4. However, wild-type ARIP4 binds to the reconstituted 
mononucleosomes and this binding is not sequence-specific, as unlabeled poly(dI-dC)•(dI-dC) 
competes efficiently with mononucleosomes for ARIP4 complex formation. Thus, our results 
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demonstrate that ARIP4 is not a classical chromatin remodeling protein. However, we cannot 
rule out the possibility that the presence of some specific histone modifications is required for 
ARIP4 to remodel successfully mononucleosomes. In addition, some other unknown ARIP4 
interaction partners, absent in our in vitro assay, may be needed for the chromatin remodeling 
activity of ARIP4. 
 
5. ARIP4 is sumoylated (II) 
The ATPases of the SNF2 family frequently serve as core components of relatively 
stable large protein complexes (Asturias et al. 2002, Lusser and Kadonaga 2003, Smith et al. 
2003, Vignali et al. 2000). In an attempt to find ARIP4 interaction partners, we performed gel 
filtration and coimmunoprecipitation experiments. Despite many different conditions tested, 
we failed to find ARIP4 interaction partners in HeLa nuclear extracts. Thus, under our 
experimental conditions, ARIP4 does not form stable high-molecular-mass protein 
assemblies. ARIP4 seems to interact with its protein partners only weakly and/or transiently 
in such a manner that, at any given time, only a small fraction of the ARIP4 pool is involved 
in protein-protein interactions.  
A yeast two-hybrid screen using full-length wild-type ARIP4 as a bait led to the 
identification of only two biologically meaningful interacting partners for ARIP4, namely the 
small ubiquitin-related modifying protein (SUMO-1) and Ubc9. Ubc9 serves as an E2 
conjugating enzyme that, together with an E1 activating enzyme Aos1/Uba2 and several E3 
ligase enzymes, catalyzes sumoylation – a covalent attachment of SUMO-1 to lysine 
residue(s) of target proteins. Sumoylation can modulate transcriptional regulation, 
intracellular protein localization, DNA repair, and protein-protein interactions (Gill 2004, 
Muller et al. 2004, Seeler and Dejean 2003). ARIP4 contains one consensus site for SUMO-1 
attachment at Lys-664 and several other consensus-like sequences, and it is indeed modified 
by SUMO-1 in vivo. A recent report suggests that ARIP4 can also be modified by SUMO-2 
(Rosendorff et al. 2006). Interestingly, a lysine-to-arginine mutation at consensus Lys-664 
does not significantly change the ARIP4 sumoylation pattern. It is known that mutation of the 
consensus sumoylation site can promote SUMO attachment to other lysine residues in the 
protein (Hoege et al. 2002). Mutations of five other sumoylation consensus-like sites at Lys-
361, Lys-573, Lys-935, Lys-961, and Lys-1013 (Fig. 10) alter, but not abolish, ARIP4 
sumoylation, and do not significantly affect ARIP4 DNA binding and AR coactivator activity 
(Table 3). Only combining mutations of these six lysine residues (6K→6R) results in a 
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substantial decrease in ARIP4 sumoylation. As mentioned earlier, ARIP4(6K→6R) is 
incapable of DNA binding. As a result, ARIP4(6K→6R) loses its ATPase activity and cannot 
enhance AR-dependent transactivation in transient transfection assay (Table 3). It remains to 
be established whether the defect in DNA binding is a direct consequence of sumoylation 
deficiency or if it is due to inappropriate protein folding. 
 
6. ARIP4 is expressed in mouse embryo (IV) 
To study the physiological role of ARIP4, we generated Arip4+/– mice using 
embryonic stem cells with a trapped Arip4 allele available from the German Gene Trap 
Consortium (tikus.gsf.de). The gene trap vector was designed in such a fashion that after 
genomic integration the endogenous Arip4 promoter regulates expression of the lacZ gene. 
Therefore, heterozygous and homozygous embryos express β-galactosidase (β-gal) instead of 
ARIP4. Thus, whole-mount staining of these embryos with X-gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside) can reveal the ARIP4 expression pattern. 
 
 
 
Fig. 10. ARIP4 functional regions and sumoylation sites. Shaded boxes correspond to conserved motifs in 
the SNF2 ATPase domain. SUMO, sumoylation; NLS, nuclear localization signal (residues 98–114, 412–
428, and 1254–1271). Amino acid residues are numbered according to RefSeq sequence NP_109655. 
RESULTS AND DISCUSSION  
 43 
Available data indicate that ARIP4 mRNA is detectable in mouse embryo already at 
the 2-cell stage (MGI database, www.informatics.jax.org). We have demonstrated the 
presence of ARIP4 mRNA in ES cells by Northern blotting. Our whole-mount X-gal staining 
and immunostaining with affinity-purified rabbit polyclonal anti-ARIP4 antibodies show that 
ARIP4 protein is mainly expressed in the developing neural tube and limb buds during E8.5–
E12.5. Starting from E14.5, ARIP4 expression becomes virtually ubiquitous. 
 
7. ARIP4 is expressed in postnatal mouse testes (III) 
Androgen signaling through AR is one of the crucial events in testicular development. 
To understand further the role of ARIP4 as an AR coregulator, we analyzed ARIP4 
expression in the mouse testis during postnatal development. 
ARIP4 mRNA levels are low in testes from newborn mice, but become progressively 
abundant towards puberty and continue to be high through adulthood. ARIP4 protein is 
present in the nuclei of Sertoli cells at all ages studied. Starting from day 20, Sertoli cell 
nuclei possess stage-specific ARIP4 staining. In addition, Leydig cell nuclei become ARIP4-
positive. We also detected ARIP4 in germ cells, namely in spermatogonia, pachytene and 
diplotene spermatocytes. In adult testis Sertoli cell nuclei have very strong ARIP4 
immunostaining at stages II–VI and VII–VIII, and weaker at stages IX–XII. Pachytene 
spermatocyte nuclei at stages I–V are stained relatively strongly, with the XY-bodies being 
ARIP4-positive. The presence of ARIP4 in XY-bodies is not unexpected, since ARIP4 is 
sumoylated, and SUMO-1 is known to localize to XY-bodies in pachytene spermatocytes 
(Vigodner and Morris 2005). ARIP4 expression in pachytene spermatocytes is still detectable 
at stage VII, but becomes weaker from stage IX onwards. Leptotene and zygotene 
spermatocytes also exhibit some immunostaining. In general, weak ARIP4 immunostaining in 
spermatocytes is detectable throughout development. Early round spermatids appear faintly 
stained, whereas all other spermatids are negative. 
We turned to heterozygous Arip4+/– mice to study how the reduction in ARIP4 levels 
affects the testicular phenotype. Despite having reduced ARIP4 mRNA and protein levels, 
Arip4+/– mice are fertile, appear normal, and have normal testicular histology. The expression 
pattern of ARIP4 antigen in testes from Arip4+/– mice is similar to that of wild-type testes, 
with positive Leydig and Sertoli cell nuclei, spermatogonia, pachytene and diplotene 
spermatocytes. Sertoli cell nuclei have a strong ARIP4 immunostaining at stages II–VI and 
VII–VIII, and a strong AR immunostaining at stages VII–VIII. Thus, the disruption of one 
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Arip4 gene allele in Arip4+/– mice does not qualitatively change either testicular histology, 
ARIP4 or AR expression patterns. However, we detected quantitative changes in mRNA 
levels of androgen-dependent Rhox5 and Eppin proteins (Denolet et al. 2006, Lindsey and 
Wilkinson 1996, Sivashanmugam et al. 2003), indicating that Arip4+/– mice are 
haploinsufficient with regard to AR-specific gene expression in Sertoli cells. 
 
8. Expression of ARIP4 in testis of adult wild-type, FSHRKO, LuRKO, and 
hpg mice (III) 
Stage-dependent expression of ARIP4 in Sertoli cell nuclei closely resembles that of 
AR. ARIP4 expression is high at stages II–VI and, similar to AR, peaks at stages VII–VIII. 
The mechanisms governing the stage-dependent protein expression in Sertoli cells are poorly 
understood. To investigate how the disruption of hormonal signaling in testis influences 
ARIP4 and AR expression, we studied the testes from LuRKO, FSHRKO, and hpg mice. 
In adult LuRKO mice, the testicular testosterone concentration is reduced by 97% in 
comparison to wild-type mice (Zhang et al. 2004). AR and FSHR mRNA levels are 
significantly higher in the testes of LuRKO mice than in wild-type testis, whereas ARIP4 
mRNA levels in LuRKO testes do not differ from wild-type. However, neither Lhr nor Fshr 
knockout qualitatively affect testicular distribution and stage-specific expression of ARIP4 
and AR proteins.  
Sertoli cells in hpg testes develop atypically, and their morphology resembles that of 
10-day-old wild-type testes (Myers et al. 2005). In the testis of hpg mice, ARIP4 protein is 
detected mainly in interstitial cells, whereas ARIP4 expression in Sertoli and germ cells in 
hpg testis is much lower then that in 10-day-old wild-type testis. At present, we can only 
speculate whether the reduced ARIP4 protein expression in Sertoli and germ cells is linked to 
spermatogenesis arrest in hpg testis. 
Thus, disruption in testosterone, FSH, or LH signaling has a limited, if any, influence 
on the pattern of ARIP4 and AR expression in the testis. Accordingly, in vitro treatments of 
seminiferous tubule segments with testosterone, FSH, or forskolin for 4, 8, or 16 h do not 
significantly change ARIP4 mRNA levels. 
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9. Targeted disruption of mouse Arip4 gene results in embryonic lethality 
(IV) 
Genotyping of the progeny of Arip4+/– intercrosses demonstrates the expected 
Mendelian frequencies of both wild-type and heterozygote offspring. However, the 
homozygote pups are totally absent, indicating that Arip4–/– embryos are not viable. Most 
Arip4–/– embryos appear to develop normally up to E8.5, but no homozygous embryos are 
recovered from E11.5 onwards. The body size of Arip4–/– embryos is significantly reduced 
compared to that of wild-type littermates at E9.5 and E10.5. Histological analyses do not 
reveal any obvious developmental defects. However, almost all tissues of Arip4–/– embryos at 
E10.5 are proportionally smaller than those of wild-type embryos. The yolk sac and placenta 
of Arip4–/– embryos appear normal, and thus the embryonic lethality is unlikely due to the 
failure of embryonic blood circulation. 
ARIP4 coimmunoprecipitates with transcriptional corepressor CtBP1 (Fig. 11). Mice 
lacking Ctbp1 are viable, however, 
knockout of the highly homologous 
Ctbp2 results in embryonic lethality 
at E10.5. Ctbp2 null embryos are 
smaller and have defects in heart 
morphogenesis and in neural 
system development (Chinnadurai 
2003, Hildebrand and Soriano 
2002). Similarly, knockout of 
ARIP4-interacting Dyrk1a results in 
embryonic lethality between E10.5 
and E13.5. Dyrk1a–/– embryos 
exhibit significant growth 
retardation and defects in 
morphology of the heart, liver 
primordium, branchial arches, and 
brain vesicles (Fotaki et al. 2002). At E9.5 CtBP1, CtBP2, Dyrk1A, and ARIP4 are expressed 
in developing neural tubes (Fotaki et al. 2002, Hildebrand and Soriano 2002). Interestingly, 
AR is also present in developing nervous system, but its expression occurs later during 
embryonic development (Kerr et al. 1995, Young and Chang 1998). The obvious phenotypic 
 
 
                          1          2 
 
Fig. 11. ARIP4 interacts with CtBP1. COS-1 cells were 
transiently transfected with 100 ng of pcDNA-CtBP1 together 
with 700 ng pFLAG-CMV2 (lane 1) or pFLAG-ARIP4wt (lane 
2). Immunoprecipitation and immunoblotting were performed 
as described in (II) using anti-FLAG M2 antibody (Sigma-
Aldrich, St. Louis, MO) and anti-CtBP1 antibody (a gift from 
Dr. Qinghong Zhang, Oregon Health Sciences University, 
Portland, OR). 
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similarity among Ctbp2–/–, Dyrk1a–/–, and Arip4–/– embryos suggests that ARIP4-CtBP and 
ARIP4-Dyrk1A interactions may play important roles during early neural development. 
 
10. ARIP4 influences apoptosis and cell proliferation (IV) 
To further understand the molecular mechanisms causing embryonic lethality, we 
studied cell proliferation and apoptosis in E9.5 and E10.5 embryos. TUNEL staining 
indicated that at E9.5 and E10.5 Arip4–/– embryos have a higher proportion of apoptotic cells, 
especially in the neural tube. The neural tube of Arip4–/– embryos at E9.5 and E10.5 has a 
reduced proportion of proliferating phospho-histone H3-positive cells. Mouse embryonic 
fibroblasts (MEFs) derived from Arip4 null embryos at E9.5 also exhibit impaired 
proliferation and increased apoptosis. These cells stop growing after 2–3 passages and have 
significantly lower growth rate than cells from wild-type littermates.  
Microarray analysis of total mRNA expression profiles in E9.5 Arip4–/– and wild-type 
embryonic fibroblasts revealed that the expression of several apoptosis- and cell proliferation-
related genes is deregulated in Arip4–/– MEFs. Deletion of ARIP4 also affects the expression 
of several genes involved in apoptosis and cell death, DNA replication and repair, 
neurogenesis, and development. Using quantitative real-time PCR we have confirmed the 
microarray results for several key genes involved in apoptosis, development, and cell growth 
and maintenance. Obviously, not all of these genes have to be direct targets of ARIP4. 
Observed deregulation of some genes can be a secondary effect due to general proliferation 
defects in E9.5 Arip4–/– fibroblasts. In order to detect the more subtle effects of ARIP4 
deletion on gene expression patterns, embryonic fibroblasts derived from embryos at earlier 
developmental stages or Arip4 null embryonic stem cells will have to be analyzed. 
Nevertheless, our results clearly demonstrate that the loss of ARIP4 affects gene expression 
pattern and proliferation of embryonic fibroblasts.  
 These results suggest that ARIP4 is involved in the regulation of apoptosis and cell 
proliferation. As we mentioned earlier, several other members of SNF2 family, including 
ATRX – an ARIP4 homolog, have been implicated in these processes (Tang et al. 2004a, 
Tang et al. 2004b, Xue et al. 2003). We could not detect AR mRNA in MEFs at E9.5. 
Therefore, ARIP4 functions in apoptosis and cell proliferation do not seem to be related to its 
activity as AR coregulator. We suggest that ARIP4 acts as a coregulator for other factors 
expressed at early stages of embryonic development. ARIP4 may influence cell proliferation 
through its interaction with Dyrk1A. Dyrk1a–/– embryos have a reduced number of 
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differentiating neuronal cells suggesting that this protein is involved in neuroblast 
proliferation (Fotaki et al. 2002). In addition, similar to other SNF2 family members, such as 
Rad54, ARIP4 may be involved in homologous recombination and DNA repair processes. 
 
11. Future directions 
Our current results suggest that ARIP4 plays a dual role in embryonic development 
and adult life. At E8.5–E10.5, ARIP4 is mainly expressed in the neural tube and limb buds, 
being involved in the processes of cell proliferation and apoptosis (IV). At later embryonic 
stages, ARIP4 becomes ubiquitously expressed and may modulate AR functions in male sex 
determination and differentiation. ARIP4 expression continues after birth. We have 
thoroughly followed postnatal expression of ARIP4 in the testis (III) and also demonstrated 
the ubiquitous expression of ARIP4 mRNA in adult mouse tissues (I). ARIP4 appears to 
modulate AR activity in somatic cells of the testis (III) and in hippocampal neurons (Sitz et al. 
2004). Levels of ARIP4 mRNA are increased in advanced stages of prostate cancer and, 
therefore, ARIP4 may also be involved in prostate cancer progression (Linja et al. 2004). 
Finally, ARIP4 expression in AR-negative germ cells in adult testis implies that the protein 
has AR-independent functions in adult mouse (III). 
Future studies need to be focused on analyzing the molecular mechanisms underlying 
ARIP4 action. Detectable amounts of ARIP4 protein are present in testicular teratoma-derived 
F9 cell line and in kidney-derived 293T cells (our unpublished results). The effects of small 
interfering RNA (siRNA)-mediated ARIP4 knockdown in these ARIP4-expressing cell lines 
may reveal new ARIP4 functions. Possible roles of ARIP4 in DNA repair and homologous 
recombination can be addressed by studying the response of ARIP4-depleted cells to DNA-
damaging agents and/or ionizing radiation. Genome-wide comparison of gene expression 
patterns in wild-type and ARIP4-depleted cell lines, as well as Arip4 null fibroblasts or 
embryonic stem cells, will lead to identification of new ARIP4 target genes. Potential ARIP4 
target genes can also be identified by genome-wide mapping of ARIP4 binding sites using a 
combination of chromatin immunoprecipitation with microarrays (ChIP on chip) method. 
Recently, this method was successfully applied to map estrogen receptor binding sites on 
chromosomes 21 and 22 (Carroll et al. 2005). 
The early embryonic lethality of Arip4–/– embryos precludes phenotypic analysis of 
Arip4 null adult mice. However, recently the original gene trap method has been modified to 
allow creation of conditional trapped alleles (Schnutgen et al. 2003, Schnutgen et al. 2005). 
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Embryonic stem cells having conditional trapped Arip4 are available from the German Gene 
Trap Consortium (tikus.gsf.de). Generation of mice with conditional mutations in the Arip4 
gene, especially testis- and brain-specific Arip4 knockout mice, will undoubtedly reveal new 
fascinating details of ARIP4 function. 
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CONCLUSIONS 
 ARIP4 functions as AR coregulator in vitro and in vivo (I, II, III). We have 
characterized the biochemical properties of ARIP4 (I, II) and the expression and regulation of 
ARIP4 in mouse testis during postnatal development (III). We suggest that the ARIP4-AR 
interaction plays a role in postnatal testis development and spermatogenesis. In addition, our 
results clearly demonstrate that ARIP4 has an essential role in embryonic development and 
cell proliferation (IV). In summary, this study demonstrates that: 
• ARIP4 is a nuclear protein that interacts with AR and modulates AR-dependent 
transactivation. 
• ARIP4 binds to DNA and mononucleosomes, and it exhibits an ATPase activity that is 
dependent on double- and single-stranded DNA. However, in contrast to some other 
members of the SNF2 family, ARIP4 is not an active ATP-dependent 
mononucleosome remodeler. 
• ATPase activity and the ability to bind DNA are critical for the coregulatory function 
of ARIP4. 
• During embryonic development, ARIP4 is mainly expressed in the neural tube and 
limb buds. ARIP4 mRNA is ubiquitous in adult mouse tissues, with the highest levels 
found in liver, kidney, and testis. 
• In testis, ARIP4 is mainly expressed in Sertoli cells, Leydig cells, spermatogonia, 
pachytene and diplotene spermatocytes. In Sertoli cells, ARIP4 protein expression is 
high at stages II–VI and VII–VIII. 
• Heterozygous Arip4+/– mice appear normal, but are haploinsufficient with regard to 
AR-specific gene expression in Sertoli cells. 
• Homozygous Arip4–/– embryos show severely retarded growth at E10.5, die by E11.5, 
and are completely resorbed at E12.5. The embryonic lethality during early 
organogenesis is associated with increased apoptosis and impaired cell proliferation. 
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